利格列汀治疗新诊断2型糖尿病的随机对照研究

A Randomized Case-control Study of Trajenta for Newly Diagnosed Type 2 Diabetes Mellitus

目的评价利格列汀对新诊断2型糖尿病患者的治疗效果。方法收集2014年6月1日-2016年12月31日经鞍山市第三医院诊断的130例2型糖尿病患者作为研究对象，分为观察组和对照组各65例。观察组应用利格列汀片十二甲双胍片进行治疗，对照组应用二甲双胍片＋安慰剂治疗，两组均治疗12周，比较两组的治疗效果。结果组内比较：两组治疗前后空腹血糖、餐后2h血糖和糖化血红蛋白差异有统计学意义（P〈0．05）；体重指数差异无统计学意义（P〉0．05）。组间比较：治疗后观察组餐后2h血糖和糖化血红蛋白低于对照组低，差异有统计学意义（P〈0．05）；两组不良反应发生差异无统计学意义（P〉0．05）。结论利格列汀对新诊断2型糖尿病的治疗效果较好，未增加不良反应发生率。

Objective The aim of the study is to evaluate the therapy effect of trajenta for newly diagnosed type 2 diabetes mellitus. Methods A total of 130 newly diagnosed type 2 diabetes mellitus patients, which were collected from June 1, 2014 to December 31, 2016, were randomly divided into study group （n=65） and control group （n=29）. The Study group was treated with trajenta and metformin and the control group was treated with metfbrmin and placebo. The patients in both groups were treated for 12 weeks, and the therapy effects were compared. Results There were significant differences in fasting blood glucose （FPG）, 2 hour plasma glucose （2 hPG） and hemoglobin Alc （HbAlc） levels between before and after treatment in intra-group comparison （P〈0.05）, and no significant differences in BMI （P〉0.05）. After treatment, 2 hPG and HbAlc levels in study group were significantly lower than those in control group （P〈0.05）, and adverse reaction was no significantly different between two groups （P〉0.05）. Conclusion Trajenta has a good clinical efficacy for newly diagnosed type 2 diabetes mellitus and does not increase adverse reaction rate.